Audentes Therapeutics have published a letter, dated August 2019, for our Patient Community which can be accessed below. The letter provides details about their next steps for the AT132 Gene Therapy Clinical Trial Programme known as ‘ASPIRO’.  Letters in other languages will be published here when available.

It is important to understand that regulatory agencies have not approved the Audentes investigational gene therapy product candidate or determined that it is safe or effective, as it is still undergoing formal assessment in clinical trials.

Also, the investigational gene therapy product is not approved for commercial sale and is only available in clinical trial settings.

Audentes Therapeutics Letter to XLMTM Patient Community AUG2019 in English (updated)